Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF ACCRUED EXPENSES (Details)

v3.23.3
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued pre-clinical and clinical costs $ 1,055,116 $ 2,137,317
Accrued product development costs 509,698 247,500
Accrued license costs 2,825,000 0
Accrued compensation 1,669,980 2,224,951
Accrued administrative costs 261,921 473,376
Accrued interest 1,224,066 916,108
Total $ 7,545,781 $ 5,999,252